0
0
Amsterdam, Netherlands – A new study reveals that automated insulin delivery (AID) systems can significantly improve blood sugar control in individuals with insulin-treated type 2 diabetes (T2D) without increasing the risk of hypoglycemia. The findings, presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 2025 meeting and published in The New England Journal of Medicine, mark a significant step forward in diabetes management.
The study, known as the 2IQP trial, focused on Tandem Diabetes Care’s Control-IQ+ algorithm, which recently received FDA clearance for T2D in February 2025. This algorithm, used in conjunction with Tandem’s t:slim X2 and Mobi insulin pumps and a compatible continuous glucose monitor (CGM), allows for automated insulin adjustments.
The trial involved 319 participants with T2D who were using both basal and mealtime insulin. Participants were randomly assigned to either use the AID system or continue their usual insulin delivery method while using a CGM.
Researchers found that the AID system led to a significant reduction in A1c levels, a key measure of long-term blood sugar control. The mean A1c level decreased by 0.9 percentage points in the AID group, from 8.2% to 7.3%. Notably, the time spent in the target glucose range (70-180 mg/dl) increased significantly in the AID group, without a corresponding increase in hypoglycemia.
“In a diverse population of adults with insulin-treated type 2 diabetes, the use of AID safely reduced glycated hemoglobin levels and hyperglycemia without increasing hypoglycemia as compared with a control group using CGM,” stated Dr. Yogish C. Kudva of Mayo Clinic, lead author of the study.
Experts like Dr. Charles M. Alexander, an Independent Industry Consultant, expressed optimism about the potential of AID systems in T2D management. “It’s nice to see substantial improvement in glycemic control without any increase in hypoglycemia. All the subgroups showed the same improved glycemic efficacy compared to basal-bolus insulin,” he commented.
However, Dr. Alexander also highlighted potential challenges, including access and affordability. He noted that while AID could become standard of care for basal-bolus insulin-using T2D, it may not be suitable for all individuals with T2D, particularly those managed with oral medications or non-prandial insulin.
The study also demonstrated that previous experience with insulin pumps or advanced carbohydrate counting was not necessary for successful AID use. Most participants used a simple fixed-bolus regimen.
The research team observed minimal adverse events, with only one severe hypoglycemia event reported in the AID group. The majority of device-related hyperglycemia events were due to infusion set failures.
The results suggest that AID systems, like Tandem’s Control-IQ+, can significantly improve glycemic control in individuals with insulin-treated T2D, offering a promising new tool in diabetes management.
Disclaimer:
- This news article is based on information available as of March 20, 2025, and may not reflect the most current research or clinical guidelines.
- Medical information provided here is for general knowledge purposes only and does not constitute medical advice.
- Individuals with diabetes should consult with their healthcare providers to determine the most appropriate treatment plan for their specific needs.
- The opinions expressed by experts quoted in this article are their own and do not necessarily reflect the views of this publication.
- Financial disclosures from the researchers are included in the article to provide transparency.
- Access and affordability of AID systems may vary based on insurance coverage and other factors.
(https://www.medscape.com/viewarticle/automated-insulin-delivery-system-helps-type-2-diabetes-2025a10006jj)
